Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

被引：27
|
作者：
Javle, Milind M.
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Personeni, Nicola
Adeva, Jorge
Bergamo, Francesca
Malka, David
Vogel, Arndt
Knox, Jennifer J.
Evans, T. R. Jeffry
Dimova-Dobreva, Miryana
Harris, William Proctor
Saulay, Mikael
Engelhardt, Marc
Braun, Stephan
Busset, Michele Droz Dit
Borad, Mitesh J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[4] Hosp Univ Vall dHebron, Barcelona, Spain
[5] Ist Clin Humanitas, Humanitas Canc Ctr, Rozzano, Italy
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Oncol 1, Padua, Italy
[8] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[9] Hannover Med Sch, Hannover, Germany
[10] Univ Hlth Network, Wallace McCain Ctr Pancreat Canc, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Basilea Pharmaceut Int Ltd, Basel, NJ, Switzerland
[13] Univ Washington, Seattle Canc Care Alliance SCCA, Seattle, WA 98195 USA
[14] Natl Inst Canc, Dept Hepatopancreatobiliary Surg & Liver Transpla, Milan, Italy
[15] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
427
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
    Moehler, M.
    Goyal, L.
    Meric-Bernstam, F.
    Hollebecque, A.
    Morizane, C.
    Valle, J. W.
    Karasic, T. B.
    Abrams, T. A.
    Kelley, R. K.
    Cassier, P.
    Furuse, J.
    Klumpen, H. -J
    Chang, H. -M
    Chen, L. -T
    Komatsu, Y.
    Masuda, K.
    Ahn, D.
    He, Y.
    Soni, N.
    Benhadji, K. A.
    Bridgewater, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 222 - 222
  • [22] Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study
    Sasaki, Motoko
    Sato, Yasunori
    Nakanuma, Yasuni
    VIRCHOWS ARCHIV, 2024, 484 (06) : 915 - 923
  • [23] A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.
    DeLeon, Thomas
    Alberts, Steven R.
    McWilliams, Robert R.
    Hubbard, Joleen Marie
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Mody, Kabir
    Roberts, Lewis R.
    Salomao, Marcela
    Kipp, Benjamin
    Halfdanarson, Thorvardur Ragnar
    Murtaza, Muhammed
    Ramanathan, Ramesh K.
    Dueck, Amylou C.
    Borad, Mitesh J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
    Hollebecque, A.
    Goyal, L.
    Meric-Bernstam, F.
    Furuse, J.
    Moehler, M.
    Vogel, A.
    Liu, X.
    Wacheck, V.
    Bridgewater, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S163 - S163
  • [25] The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
    Salati, Massimiliano
    Caputo, Francesco
    Baldessari, Cinzia
    Carotenuto, Pietro
    Messina, Marco
    Caramaschi, Stefania
    Dominici, Massimo
    Bonetti, Luca Reggiani
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7747 - 7757
  • [26] Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
    Busset, Michele Droz Dit
    El-Rayes, Bassel F.
    Harris, William Proctor
    Damjanov, Nevena
    Masi, Gianluca
    Rimassa, Lorenza
    Bhoori, Sherrie
    Niger, Monica
    Personeni, Nicola
    Braiteh, Fadi S.
    Lonardi, Sara
    Braun, Stephan
    Engelhardt, Marc
    Saulay, Mikael
    Schwartz, Brian E.
    Kazakin, Julia
    Shaib, Walid Labib
    Mazzaferro, Vincenzo
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
    Goyal, Lipika
    Meric-Bernstam, Funda
    Hollebecque, Antoine
    Morizane, Chigusa
    Valle, Juan W.
    Karasic, Thomas Benjamin
    Abrams, Thomas Adam
    Kelley, Robin Kate
    Cassier, Philippe Alexandre
    Furuse, Junji
    Klumpen, Heinz-Josef
    Chang, Heung-Moon
    Chen, Li-Tzong
    Komatsu, Yoshito
    Masuda, Kunihiro
    Ahn, Daniel H.
    Li, Kate
    Benhadji, Karim A.
    Wacheck, Volker
    Bridgewater, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.
    Goyal, Lipika
    Meric-Bernstam, Funda
    Hollebecque, Antoine
    Morizane, Chigusa
    Valle, Juan W.
    Karasic, Thomas B.
    Abrams, Thomas A.
    Kelley, Robin Kate
    Cassier, Philippe
    Furuse, Junji
    Klumpen, Heinz-Josef
    Chang, Heung-Moon
    Chen, Li-Tzong
    Komatsu, Yoshito
    Masuda, Kunihiro
    Ahn, Daniel
    He, Yaohua
    Soni, Nital
    Benhadji, Karim A.
    Bridgewater, John A.
    CANCER RESEARCH, 2021, 81 (13)
  • [29] Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
    Bridgewater, J.
    Meric-Bernstam, F.
    Hollebecque, A.
    Valle, J. W.
    Morizane, C.
    Karasic, T.
    Abrams, T.
    Furuse, J.
    Kelley, R. K.
    Cassier, P.
    Klumpen, H-J.
    Uboha, N.
    Mahipal, A.
    Mitchell, E.
    Ahn, E. R.
    Chang, H-M.
    Masuda, K.
    He, Y.
    Benhadji, K.
    Goyal, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S261 - S262
  • [30] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study
    Necchi, A.
    Todenhoefer, T.
    Deville, J-L
    Hackl, M.
    Marszewska, M.
    Mckernan, P.
    Saulay, M.
    Engelhardt, M.
    De Santis, M.
    EUROPEAN UROLOGY, 2023, 83 : S783 - S783
12345